抗合成酶综合征肾脏受累的系统综述
81%的病例肾脏病与间质性肺病(ILD)同时或其后出现。35例活检患者中,膜性肾病占29%、寡免疫新月体肾小球肾炎占23%、急性肾小管坏死占17%、肾小管间质性肾炎占11%。非Jo1抗体在血管炎表型中占优势,且与更高峰值肌酐相关(4.7 vs 2.3 mg/dl;P = 0.01)。
要点
- ASyS肾脏受累多与ILD相伴出现,应常规进行肾脏监测。
- 非Jo1抗体可能与更差肾脏结局相关,但需前瞻性验证。
- 活检常见膜性肾病、寡免疫新月体肾炎、急性肾小管坏死及肾小管间质性肾炎。
核心结论
- ASyS肾脏受累具有重要临床意义,非Jo1血清型可能预示更差肾脏结局,但需前瞻性队列验证。
研究设计与样本
- 遵循PRISMA 2020指南的系统综述(PROSPERO: CRD420261282317),检索MEDLINE、Scopus、Web of Science和Google Scholar从建库至2026年1月。
- 采用Joanna Briggs Institute工具评估偏倚风险,GRADE框架评价证据确定性。
主要发现
- 81%的病例肾脏病与间质性肺病(ILD)同时或其后出现。
- 35例活检患者中,膜性肾病29%、寡免疫新月体肾小球肾炎23%、急性肾小管坏死17%、肾小管间质性肾炎11%。
- 非Jo1抗体在血管炎表型中占优势,且与更高峰值肌酐相关(4.7 vs. 2.3 mg/dl;P = 0.01)。
- 糖皮质激素单药治疗使48%的轻度疾病患者完全恢复,利妥昔单抗在8例难治性病例中6例有效。
- 中位随访18个月时,13%进展至慢性肾脏病(CKD)4期和5期。
临床怎么用
- 对ASyS患者应常规进行肾脏监测,包括尿检和肾功能评估。
- 早期基于抗体指导的免疫抑制治疗可能改善结局,但尚待验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Antisynthetase syndrome (ASyS) is a rare autoimmune disorder characterized by autoantibodies targeting aminoacyl-tRNA synthetases. Kidney involvement has been historically regarded as uncommon and remains poorly characterized. METHODS: We conducted a systematic review using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines (PROSPERO: CRD420261282317). MEDLINE, Scopus, Web of Science, and Google Scholar were searched from inception to January 2026. We included adults with biopsy-proven or clinically defined kidney involvement in ASyS. Risk of bias was assessed using Joanna Briggs Institute tools; certainty of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation framework. RESULTS: Thirty-eight articles comprising 52 patients were included. Kidney disease presented with or following interstitial lung disease (ILD) in 81% of cases. Among 35 biopsied patients, membranous nephropathy (29%), pauci-immune crescentic glomerulonephritis (23%), acute tubular necrosis (17%), and tubulointerstitial nephritis (11%) were identified. Non-Jo1 antibodies predominated in vasculitic phenotypes and were associated with higher peak creatinine than anti-Jo1 (4.7 vs. 2.3 mg/dl; P = 0.01). Corticosteroid monotherapy achieved complete recovery in 48% of mild disease, whereas rituximab was effective in 6 of 8 refractory cases. At a median of 18 months follow-up, 13% progressed to chronic kidney disease (CKD) stages 4 and 5. CONCLUSION: Kidney involvement in ASyS carries substantial clinical significance. Non-Jo1 serotype may predict worse kidney outcomes, though this association requires confirmation in prospective cohorts with multivariable adjustment. Routine kidney surveillance and early antibody-guided immunosuppression may improve outcomes, pending validation.
引用
- Wu QS, Yang L, Lin X, et al. Systematic Review of Kidney Involvement in Antisynthetase Syndrome. Kidney Int Rep. 2026. PMID: 42438724. doi:10.1016/j.ekir.2026.106669
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。